Key words: SCF micronization, risperidone, polymorphism
Comparative studies of supercritical fluid micro nization processes of 50-100 mm size risperidone pharmaceutical substrate using RESS and SAS approaches are performed to enhance its bioavailability in human body. Both micronization approaches allow obtaining risperidone microparticles of 5-20 mm size. SAS approach, however, is more preferable for effective risperidone micronization, since unlike RESS it doesn't cause any detectable contamination of risperidone with organic co-solvent residuals (used in these processes) and also allows obtaining risperidone microparticles of different shapes. It was revealed that SAS micronization process causes a change of risperidone polymorphous form from triclinic to monoclinic.
doi:10.1134/S1990793112070019